# UCSF Adult COVID-19 Management Guidelines

<table>
<thead>
<tr>
<th>Category</th>
<th>Recommendations</th>
</tr>
</thead>
</table>
| **Outpatient, asymptomatic** | • Supportive care  
• Recommend against steroids |
| **Outpatient, symptomatic** | • Supportive care for most  
• Prioritize clinical trials if eligible  
• High-risk for progression: Consider EUA monoclonal antibodies (mAbs)  
• Recommend against steroids |
| **Inpatient, asymptomatic or mild symptoms and hospitalized for non-COVID-19 reason** | • Supportive care  
• Can consider mAbs if admitted for alternative diagnosis and otherwise qualifies  
• Recommend against steroids or other anti-inflammatories |
| **Inpatient, hospitalized for COVID-19 but does not require supplemental oxygen** | • High-risk for progression or radiographic evidence of LRTI: Remdesivir x 5 days  
• <72h from symptom onset and high-risk for progression (see below): Consider CCP  
• Recommend against steroids or other anti-inflammatories |
| **Inpatient, Supplemental oxygen via nasal cannula** | • Remdesivir x 5 days  
• <72h from symptom onset and high-risk for progression (see below): Consider CCP  
• Steroids if: Persistent hypoxia requiring ≥ 3-4L O2 OR trajectory suggests increasing severity of disease |
| **Inpatient, Requires supplemental oxygen via high-flow nasal cannula or non-invasive ventilation** | • Remdesivir x 5 days  
• Steroids recommended  
• Consider adding baricitinib to steroids if recently hospitalized (e.g. within 3-4 days) and rapid clinical worsening |
| **Inpatient, Requires mechanical ventilation or ECMO** | • Remdesivir x 5 days; can consider extension to 10 days if ongoing severe illness at day 5  
• Steroids recommended  
• If baricitinib was initiated before intubation, continue the course of medication but do not initiate after intubation  
• Use tocilizumab if hospitalized < 3 days AND in ICU < 24 h AND rapidly progressing to mechanical ventilation or requiring mechanical ventilation.  
• Do not administer baricitinib and tocilizumab together |
Table 1. Diagnostic testing for patients with confirmed or suspected COVID

<table>
<thead>
<tr>
<th>Testing for COVID-19.</th>
<th>Repeat PCR testing:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initial testing for symptomatic patients:</strong></td>
<td>If negative initial PCR and very high suspicion:</td>
</tr>
<tr>
<td>COVID-19 PCR via</td>
<td>o Tracheal aspirate COVID-19 PCR in mechanically ventilated patients</td>
</tr>
<tr>
<td>Nasopharyngeal (NP) +/- Oropharyngeal (OP), Mid-Turbinate</td>
<td>o Repeat NP or MNT + OP testing if not mechanically ventilated</td>
</tr>
<tr>
<td>(MNT) +/- OP, or Anterior Nares (AN) +/- OP (note that flu/RSV and RVP cannot be performed on AN samples)</td>
<td>Certain COVID-19 confirmed patients may require additional testing for disposition; consult ID to discuss next steps</td>
</tr>
</tbody>
</table>

Retesting of previously negatively tested patients should be done if:
- New compatible symptoms
- Exposure investigation
- Planned or continuous aerosol-generating procedure (every 7 days)
- Shared room (Monday and Thursday)

**Serologic testing, clinical indications:**
- Confirmation of infection if high clinical suspicion, negative PCR testing, and symptoms > 7 days
- Documentation of serological response prior to convalescent plasma donation
- Utility for determining immunity uncertain

**Laboratory testing**

**On admission**

*All patients*:
- CBC with differential, BMP, LFTs, coagulation studies
- Consider SARS-CoV-2-Ab IgG Nucleocapsid Protein if planning CCP

**Routine monitoring:**
- If receiving medications to treat COVID-19, obtain daily CBC with differential, BMP, Mg
- Trend LFTs Q48h-72h if abnormal at baseline (> 2 x ULN) or receiving remdesivir therapy
V.12
9.8.21
Owner: Care Delivery Committee

- Send RVP if during flu season (declared by HEIP and executive leadership based on Bay Area flu incidence)

**If clinically indicated:**
- Procalcitonin, troponin, BNP, lactate, ABG
- If concern for bacterial infection (prior to starting empirical antibiotics): blood cultures (2 sets), sputum bacterial culture
- Hepatitis B and C serologies if elevated liver biochemistries
- Consider to estimate risk for severe disease: fibrin d-dimer, CRP, LDH and CPK.

**If clinical deterioration:**
- Repeat sputum and blood cultures (tracheal aspirate culture if intubated)

**Do not obtain unless clinical suspicion for a specific diagnosis (e.g. HLH):**
- Ferritin, soluble IL-2-receptor-alpha, NK cell activity

**Do not obtain:**
- IL-6 levels

**Imaging**

**Chest radiograph:**
- Baseline AP CXR on admission
- Monitoring for complications (pneumothorax, atelectasis) at interval deemed appropriate by clinical team

**Chest CT:**
- Limited role in diagnosis of COVID-19 (PCR test of choice)
- Primary role is evaluation of superimposed processes such as pulmonary embolism or aortic dissection.

---

**Table 2. Therapeutics**

**Therapies**
- Multiple clinical trials continue to enroll inpatients and outpatients
- Clinical trial teams will screen inpatients for eligibility and offer enrollment
- Experimental therapeutics should only be offered in the context of a clinical trial

**Antibiotics**
- Bacterial co-infection on initial presentation to the hospital for COVID-19 is uncommon. Use antibacterials sparingly in this population, and if started, deescalate rapidly for negative cultures.
For patients admitted with severe and critical COVID-19, hospital-acquired infections may occur with both bacterial and fungal pathogens. Decisions to initiate therapy should be based on clinical data.

| Baricitinib or tocilizumab | Recent studies of JAK inhibitors, including baricitinib, have demonstrated reduced disease progression and decreased mortality in patients requiring significant oxygen support. Other studies of IL-6 inhibitors, including tocilizumab, show improved clinical outcomes and decreased mortality, especially in recently admitted patients in the ICU requiring intubation. Updated NIH guidance recommends “using either baricitinib (BIIa) or tocilizumab (BIIa) (listed alphabetically) in combination with dexamethasone alone or dexamethasone plus remdesivir for the treatment of COVID-19 in hospitalized patients on high-flow oxygen or noninvasive ventilation who have evidence of clinical progression or increased markers of inflammation.” The NIH Panel could not reach consensus on a recommendation for use of either medication for patients with signs of systemic inflammation and rapidly increasing oxygen needs while on steroids but not requiring non-invasive ventilation or high flow oxygen. The NIH panel did not comment on their prior recommendation to use tocilizumab in recently admitted patients requiring ICU care < 24h and mechanical ventilation. |

In consideration of these NIH recommendations, and new baricitinib clinical trial data, our updated guidance:

- Consider baricitinib if the following criteria are met:
  - Use with steroids (preferred, meets all below):
    - Severe or critical disease and meets criteria for steroids
    - Recent hospitalization
    - Escalating oxygen via nasal cannula, high flow oxygen, or non-invasive ventilation
  - Use in place of steroids:
    - Meets criteria for steroids AND
    - Has a contraindication to steroids
- Baricitinab dosing:
4 mg PO once daily up to 14 days while in the hospital
- Adjust dosing for renal failure as follows:
  - CrCl 30-59 mL/min: 2 mg PO once daily
  - CrCl 15-29 mL/min: 1 mg PO once daily
- **Contraindications:**
  - CrCl < 15 mL/min
  - Use with caution in immunocompromised patients
  - Discontinue if absolute lymphocyte count < 200 cells/ml or ANC < 500 cells/ml. Can restart once above these thresholds.
  - Interrupt treatment if drug-induced liver injury is suspected or if ALT and/or AST rises to > 10x upper limit of normal

- Use tocilizumab as an alternative to baricitinib if hospitalized < 3 days AND in ICU < 24 hours AND rapid disease progression with imminent requirement for mechanical ventilation or already requiring mechanical ventilation.
  - Administer with steroids.
- **Tocilizumab dosing:** 8 mg/kg IV x 1 dose (maximum dose: 800 mg)
  - **Contraindications:**
    - Serious concomitant infection
    - Use with caution in immunocompromised patients, especially if recent immunomodulating drugs
    - Lab abnormalities: ANC < 500, platelets < 50, ALT > 5x ULN

- Do not administer baricitinib and tocilizumab together
- ID consultation recommended for use of both baricitinib and tocilizumab.
- Avoid use of these agents in pregnancy given lack of safety data. Both agents may be used during lactation. If baricitinib is administered, breastmilk should be discarded until 3 days after last dose. Consult with OB and pharmacy prior to administration.
- Both agents require ID approval for this indication
| **Casirivimab and Imdevimab** | The FDA has now issued an EUA for the use of several neutralizing monoclonal antibodies (mAbs) that bind the receptor-binding domain of the SARS-CoV-2 spike protein for the treatment of outpatients with mild to moderate COVID-19. Published and unpublished data suggest that antibodies may help to augment decline in viral load and prevent a proportion of ED visits and hospitalizations. Current EUAs allows for the treatment of COVID-19 in ambulatory adults and children ≥ 12 year-old with mild to moderate disease.  
   - Consider use in high-risk outpatients  
   - **Dosing:** Casirivimab 600 mg and imdevimab 600 mg as a single IV infusion  
   - **Contraindications:**  
     - Hospitalized for COVID-19  
     - New O2 requirement  
     - Worsening O2 requirement in those on home supplemental O2  
   - Inpatient use requires ID approval. Compassionate use for inpatients may be requested on a case-by-case basis through the drug company. |
| **Convalescent plasma** |  
   - Available via EUA. Blood bank will prioritize high-titer units.  
   - Outside of clinical trial, may consider for use if:  
     - Severe immunocompromise not expected to mount an antibody response (e.g. recent solid organ transplant or stem cell transplant)  
     - Or meets the following criteria:  
       - <72 hours from symptom onset  
       - Non-severe/non-critical disease  
       - High-risk for progression  
       - Age ≥ 75 or  
       - Age ≥ 65 AND one of the following:  
         - Body mass index (BMI) ≥ 35  
         - DM with poor control or requiring medical treatment  
         - Hypertension with poor control or requiring medical treatment  
         - COPD on medical therapy  
         - Coronary heart disease |
| **Remdesivir** | **Initial data suggest some benefit in time to recovery and possibly in mortality. FDA approved**  
| | **o Treatment should be administered to hospitalized patients with evidence of lower respiratory tract infection (e.g. hypoxia, abnormal chest radiograph)**  
| | **o Dosing:** 200mg IV x 1, then 100mg IV q24h for 4 additional days; may consider 10 days on a case-by-case basis if not responding to initial course  
| | **o Vehicle contains cyclodextrin, which can accumulate in renal failure. Not well studied in renal replacement therapy (including intermittent hemodialysis), though likely to be safe given short duration of therapy. Dose adjustment is not required.**  
| | **o Contraindications:**  
| | **o ALT/AST > 10 times the upper limit of normal**  
| | **o Allergy**  
| | **o Requires ID approval (initial overnight dose is unrestricted)** |

- **Hemorrhagic or ischemic stroke**
- **Heart failure with ejection fraction < 40%**
- **≥ stage 3b chronic kidney disease (eGFR < 45 mL/min per 1.73 m²)**

- **Exclusion:** Patients who have received monoclonal antibodies for treatment of COVID-19 in prior 90 days
- **Use caution if concern for volume overload (e.g. severe liver disease, heart failure, renal failure not yet on renal replacement)**

- **Process:**
  - **Requires ID approval**
  - **Give EUA Fact Sheet ([https://www.fda.gov/media/141479/download](https://www.fda.gov/media/141479/download)) to patient or surrogate and inform them that CCP is investigational and discuss potential risks (transfusion reaction) / benefits (unclear)**
  - **Get / ensure up to date Type and Screen**
  - **Obtain standard blood product consent form**
  - **Once patient agrees, places order (under "IP Adult Standard Transfusion Orders," selection "COVID convalescent plasma")**
Initial data suggests mortality benefit in those with severe or critical disease. No benefit (and trend towards harm) seen in those who do not require supplemental oxygen. Off-label use.

**Dosing:** Dexamethasone 6 mg IV or PO qday (or equivalent) up to 10 days while in the hospital. Administer PO if able to take oral medication.

**Populations:**
- Patients undergoing mechanical ventilation, non-invasive ventilation, or high-flow nasal cannula: Most patients should be treated with steroids
- Patients on nasal cannula: Consider steroids in those with persistently low oxygen saturation and requiring substantial supplemental oxygen (e.g. ≥ 3-4L O2) or whose trajectory suggests increasing severity of disease

**Contraindications:**
- Patients who do not require supplemental oxygen should not get steroids for the indication of COVID-19

Factors to consider in determination of whether to withhold (or stop) steroids:
- Uncontrolled invasive fungal infections
- Uncontrolled hyperglycemia
- Existing delirium
- Other immunosuppressive medications
- Pregnancy (dexamethasone crosses the placenta and should be discussed with OB/Maternal-Fetal Medicine before administration)

*Consult ID for patients with any of the above factors to discuss relative risk/benefit of steroid administration*

### Steroids

<table>
<thead>
<tr>
<th>Medications to avoid</th>
<th>Other antiviral and immunomodulatory agents (e.g. hydroxychloroquine, ivermectin, fluvoxamine)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tocilizumab</td>
<td>See “baricitinib and tocilizumab” section</td>
</tr>
<tr>
<td>Anticoagulation</td>
<td>Do not give other pharmaceutical treatments specifically for COVID-19 unless part of a clinical trial</td>
</tr>
</tbody>
</table>
Prophylactic enoxaparin (standard dosing, 40 mg SQ QD; 40 mg sq BID if > 120 kg or BMI > 40) is recommended for all patients with COVID-19 except those receiving full dose anticoagulation or with contraindications (e.g. active CNS bleed, severe thrombocytopenia with platelet count < 25,000).

- Therapeutic anticoagulation can be considered in a subgroup of patients as outlined [here](#).
- If CrCl 15-30 mL/min, use enoxaparin 30 mg SQ Qdaily. If CrCl < 15 mL/min, use UFH 5000 units SQ q8 hours.
- Enoxaparin: If baseline elevated aPTT, obese, underweight, or CrCl<30, check peak anti-Xa level 4-6 hours after 3rd-4th dose to ensure appropriate dose (goal 0.2-0.5).
- If persistent clotting of lines and/or worsening clinical course, therapeutic anticoagulation may be considered via multidisciplinary discussion.

### Immunosuppression
- In immunosuppressed patients without COVID-19, do not make anticipatory adjustment to current immunosuppressive drugs or dosages.
- In immunosuppressed patients with COVID-19, consider reducing levels of immunosuppression if possible.

### Other
- **Renin-angiotensin system (RAS) blockers**
  - Theoretical concerns have been raised as some RAS blockers may increase expression of ACE2, which may facilitate viral entry into cells. However, currently there is not clinical or epidemiological data to support this concern. Patients who routinely take ACE inhibitors or ARB medications should generally continue these medications.
- **Nonsteroidal anti-inflammatory drugs**
  - Concerns have been raised that NSAIDs may worsen COVID-19 disease. However, to date, there is no scientific evidence connecting the use of NSAIDS with worsening COVID-19 symptoms or outcomes.

### Table 3: Critical Care

#### Respiratory and Ventilator Management
- Only essential providers in the room during intubation or other aerosol generating procedures.

#### Nebulizer therapy:
- Nebulizer therapy is an aerosol generating procedure and should be avoided except:
  - ICU-level care due to respiratory status
  - Requiring high-flow nasal oxygen or non-rebreather mask
| ▪ Inability to follow commands (altered mental status, severe cognitive impairment) |
| ▪ Mechanically ventilated and can be delivered in-line with circuit. |

**Non-invasive respiratory support:**
- High flow nasal oxygen (HFNO) should be considered for use in hypoxemic patients but caution with higher flows (e.g. >25 LPM) in order to avoid emergent intubation. Close monitoring of respiratory status is essential.
- Non-invasive ventilation (NIV, e.g. CPAP or BiPAP) should only be used in selected patients with respiratory failure or known obstructive sleep apnea.
- Both HFNO and NIV are aerosol generating procedures and require airborne precautions.
- Patients receiving either HFNO or NIV should be cared for in a monitored setting by personnel capable of performing endotracheal intubation.

**Intubation:**
- Emergent intubations are to be avoided given the prolonged time to apply PPE and increased risk of infection to the person performing the intubation.
- Only experienced providers should perform intubation.
- Consider video laryngoscopy as preferential airway equipment.
- Once intubated, minimize circuit disconnects and use in-line suction.

**Mechanical Ventilation and Advanced Respiratory Care:**
- Lung protective ventilation is the mainstay of care: preferred mode is volume controlled ventilation with low tidal volume (6 mL/kg predicted bodyweight) with a plateau airway pressure of less than 30 cm H2O.
- For severe hypoxemia (P/F ratio < 150) consider:
  - Moderate-high PEEP
  - Recruitment maneuvers (monitor hemodynamics and discontinue if patient develops hypotension or no improvement in driving pressure or oxygenation)
  - Deep sedation +/- neuromuscular blockade, especially with ventilator asynchrony
  - Early use of manual proning.

**Extracorporeal Membrane Oxygenation (ECMO) Considerations**
ECMO (VA or VV, as appropriate) will be considered per criteria established by Critical Care Medicine and Cardiac Surgery.

**Continuous Renal Replacement Therapy (CRRT)**
For patients with acute kidney injury (AKI), consider delaying CRRT until significant metabolic complications arise (K > 5.5 mmol/L) or until significant positive fluid balance despite high-dose diuretics or unable to achieve lung protective ventilation due to severe metabolic acidosis.

For ESRD patients, CRRT should be used to avoid markedly positive fluid balance, which may exacerbate hypoxemia.

### Table 4: Palliative Care

<table>
<thead>
<tr>
<th>Palliative Care (PC) best practices</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>For primary teams:</strong></td>
</tr>
<tr>
<td>o Perform a Goals of Care discussion within 48hrs of admission and offer age- and comorbidity-specific prognostic information</td>
</tr>
<tr>
<td>o Use the comfort care order set for actively dying patients (consult PCS only if there are questions or additional support is needed)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Indications for Palliative Care Consultation unique to patients with COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>o Consider for patients requiring ICU-level care</td>
</tr>
<tr>
<td>o Emotional, spiritual and symptomatic support at the end of life for patient/family</td>
</tr>
<tr>
<td>o Ethical decision making</td>
</tr>
</tbody>
</table>

### Caring for the Caregiver

| o The Caring for the Caregiver Program is dedicated to providing support to faculty, staff and trainees experiencing emotional distress related to the clinical care of patients |
| o Please contact caringforthecaregiver@ucsf.edu anytime to request support for yourself or a peer (can also coordinate group debriefings) |

### Table 5: Discontinuation of isolation and discharge considerations

<table>
<thead>
<tr>
<th>Discontinuation of Isolation at UCSF Health</th>
</tr>
</thead>
<tbody>
<tr>
<td>See COVID-19 Guidelines for Discontinuing of Isolation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Discharge considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>o Discharge coordination for hospitalized patients with COVID-19 requires advanced planning and close coordination between multiple disciplines in the hospital including clinicians, infection control, and case management, particularly for discharge to congregate settings</td>
</tr>
</tbody>
</table>
Case Management notifies local DPH via CMR Form Submission for new COVID + admissions
Case Management coordinates with local DPH for discharge clearance for some SNF or other facility placements
Case Management/Social work will coordinate COVID isolation transport when necessary
Explicit guidance and return precautions for evaluation of concerning symptoms after discharge must be provided (utilize prepared communications tools with anticipatory guidance)
Inpatient discharge dot-phrases:
  - .COVIDPOSINPTDCED
  - .COVIDPOSINPTDCEDES (Spanish)
Outpatient discharge dot-phrase:
  - .COVIDDISCHARGEAULT

**Self-discharge:**

- **All Patients**
  - Provider to call SF DPH AMA line at 415-608-1515
  - CM to provide local DPH isolation guidelines
- **Homeless patients**
  - Email DPH AMA recovery at covid19AMArecovery@sfdph.org (24/7, 7 days a week) and/or call 415-608-1515 (M-F 8am-8PM)
  - Include information:
    - name
    - date of birth
    - time they departed
    - whether they are a PUI or Covid Positive
    - Information about where they may have gone/phone number
  - DPH contact: Sarah Strieff RN 415-238-1485 or sarah.strieff@sfdph.org

**Discharge to Skilled Nursing Facilities**

- Case Management will coordinate with local DPH and/or admission staff to determine their ability to accept COVID patients needing isolation.
- Some SNFs are given blanket clearance from DPH to admit COVID patient
  - Many SNFs require COVID isolation period of 10 vs 20 days to be completed as well as afebrile x 24 hours prior to admission

**Discharge to Group Settings**
If the patient has the ability to isolate after discharge, they are able to return to RCFE/Group setting.

Reviewed by representatives from:
- Care Delivery Committee
- Hospital Medicine
- Critical Care Medicine
- Infectious Diseases
- Pharmacy
- Nephrology
- Case Management

References:


